ASP Isotopes Stock Price, News & Analysis

ASP Isotopes (NASDAQ: ASPI) has announced its participation in the Canaccord Genuity Sustainability Summit on Wednesday, February 26, 2025. This virtual event will feature presentations, panel discussions, and one-on-one meetings with company executives and industry experts.

Paul Mann, Chairman and Chief Executive Officer of ASP Isotopes, will join a panel discussion on the future of nuclear fission from 9:30-10:10 a.m. Eastern Time. The panel will also include Jeffrey Miller, Vice President of Business Development at TerraPower, and Christopher Colbert, Chief Executive Officer of Elementl Power.

ASP Isotopes, an advanced materials company focused on developing technology for isotope production across multiple industries, invites institutional investors to attend the virtual event by contacting their Canaccord Genuity representative.

Venu Holding (NYSE:VENU) and ASP Isotopes will be featured on RedChip's Small Stocks, Big Money show on Bloomberg TV, airing February 1, 2025, at 7 p.m. ET. During the interview, VENU's Founder, Chairman, and CEO J.W. Roth discusses the company's innovative approach to live entertainment, integrating luxury hospitality and real estate development.

VENU is expanding its portfolio with 11 new venues, including outdoor amphitheaters in Oklahoma and Texas, with plans to add $2 billion in real estate assets within 18-24 months. The company has formed partnerships with AEG Presents and NFL Hall of Famer Troy Aikman. Their Fire Pit Suite sales strategy is projected to generate $200 million in 2025, helping mitigate development risks and avoid debt burden.

ASP Isotopes (NASDAQ: ASPI) is hosting a two-day investor access event in Pretoria, South Africa, welcoming 27 investors from 9 countries. The company has achieved significant breakthroughs with its Quantum Enrichment (QE) technology, demonstrating an enrichment factor of up to 678, substantially higher than previous expectations of 50 and other laser-based approaches which achieve less than 20.

The company announced accelerated commissioning of its Silicon-28 and Ytterbium-176 facilities, with commercial production now expected in Q1 2025, ahead of previous H1 2025 timeline. The first shipment of Carbon-14 feedstock is expected to arrive in January, with a second shipment in February/March, enabling commercial production and sales in H1 2025.

Additionally, ASPI granted restricted stock awards covering 275,000 shares to two new non-executive employees, vesting over four years in eight semi-annual installments.

ASP Isotopes (NASDAQ: ASPI) shared significant milestones and future goals in a letter from CEO Paul Mann. In 2024, the company completed two isotope enrichment facilities, one for Carbon-14 and another for Silicon-28, both expected to enter commercial production in 1H 2025. They also completed a Quantum Enrichment facility for Ytterbium-176, important for producing Lutetium-177 used in prostate cancer treatment.

ASP signed contracts for Silicon-28 supply for quantum computing and AI, and a research contract with TerraPower for HALEU production. They also signed an MOU with South African Nuclear Engineering to develop advanced nuclear fuel.

The company raised $84 million in 2024 and ended Q3 with $51 million in cash. Despite a delay in Carbon-14 feedstock, first revenues are expected in 1H 2025. ASP plans to expand into Nickel-64 and Lithium-6/7 production, addressing supply chain gaps and aiming to lead in nuclear engineering.

ASP Isotopes (NASDAQ: ASPI) has issued a comprehensive response to a short seller report by Fuzzy Panda published on November 26, 2024. The company strongly refutes the report's claims, stating it contains incomplete information and misleading conclusions. ASPI clarifies that its quantum enrichment technology differs significantly from the outdated AVLIS technology referenced in the report, highlighting recent achievements including the production of enriched Ytterbium-176. The company also addresses criticisms regarding its TerraPower agreement, South African facilities, and regulatory approvals. ASPI confirms it has approximately 126 employees in South Africa and is currently commissioning three isotope enrichment facilities. The company maintains that PET Labs has generated positive EBITDA for several years, contrary to Fuzzy Panda's claims of losses.

ASP Isotopes (NASDAQ: ASPI) has announced an Investor Access Event in South Africa from January 14-16, 2025. The event will showcase the company's three isotope enrichment facilities, including tours of their Carbon-14, Silicon-28, and Ytterbium-176 production sites. Participants will also visit PET Labs and the Pelindaba facility.

The company hosted over 60 investors and corporate clients in 2024 and continues to prioritize stakeholder transparency. Interested parties must register by emailing Viktor Petkov and submit passport copies by December 31, 2024, for security clearance. The event includes scientific sessions and facility tours, with a schedule designed to accommodate US travelers.

ASP Isotopes has issued a response to a short seller report published by Fuzzy Panda Research on November 26, 2024. The company strongly disputes the report's claims, stating they contain inaccurate information and misleading speculation about the company's technology, leadership, and growth prospects. ASP Isotopes is currently commissioning three isotope enrichment facilities in South Africa, focusing on: Carbon-14 for healthcare and agrochemicals, Silicon-28 for semiconductors in AI and quantum computing, and Ytterbium-176 for radio-oncology therapies. The company will address these matters in a fireside chat with Canaccord Genuity's analyst on November 27, 2024.

ASP Isotopes (NASDAQ: ASPI) has completed construction of its Silicon-28 enrichment facility in Pretoria, South Africa, and begun commissioning phase. The facility's annual capacity is now expected to exceed 50 kilograms of Silicon-28 enriched to 99.995%, up from previous guidance of 10 kilograms. The company has secured two purchase agreements with US-based customers and anticipates first commercial deliveries in 1H 2025. The facility processes silane directly, potentially offering higher quality product without additional chemical conversion. The plant operates under International Atomic Energy Agency oversight, and the company plans to expand with additional facilities in Iceland and the United States.

ASP Isotopes (NASDAQ: ASPI) has entered into a Memorandum of Understanding with The South African Nuclear Energy (Necsa) to collaborate on research, development, and commercial production of advanced nuclear fuels, particularly High Assay Low Enriched Uranium (HALEU). The partnership involves forming a new entity in South Africa with board representation from both companies. The project will be based at Pelindaba, South Africa's main nuclear research center. This follows ASPI's recent Term Sheet with TerraPower for HALEU facility funding and purchasing agreements. The company has received interest from potential customers requiring over $37 billion of HALEU through 2037.